These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. A prospective survey on drug choice for prescriptions for admitted patients with schizophrenia. Ito C; Kubota Y; Sato M Psychiatry Clin Neurosci; 1999 Oct; 53 Suppl():S35-40. PubMed ID: 10560896 [TBL] [Abstract][Full Text] [Related]
5. [Modified variant of simultaneous discontinuation of psychotropic drugs (given in combination with diuretics) as a method of abrupt termination therapy for protracted episodes of schizophrenia]. Tsygankov BD Zh Nevropatol Psikhiatr Im S S Korsakova; 1980; 80(5):754-9. PubMed ID: 6774532 [TBL] [Abstract][Full Text] [Related]
6. [Adverse effects of long-term psychopharmacologic therapy on sexual functions]. Pfeiffer W; Kockott G; Fischl B; Schleuning G Psychiatr Prax; 1991 May; 18(3):92-8. PubMed ID: 1886955 [TBL] [Abstract][Full Text] [Related]
7. The role of psychotropic drugs in the insidious deconstruction of the Kraepelinian dichotomy. Vinar O Psychiatr Danub; 2007 Dec; 19(4):354-8. PubMed ID: 18000488 [TBL] [Abstract][Full Text] [Related]
8. Dosage and treatment strategies in schizophrenia and affective disorders. Psychopharmacol Bull; 1982 Jan; 18(1):19-26. PubMed ID: 7089158 [No Abstract] [Full Text] [Related]
9. Management of treatment resistant schizophrenia unresponsive to clozapine. Barnes TR; McEvedy CJ; Nelson HE Br J Psychiatry Suppl; 1996 Dec; (31):31-40. PubMed ID: 8968653 [No Abstract] [Full Text] [Related]
12. The treatment of negative symptoms: pharmacological and methodological issues. Carpenter WT Br J Psychiatry Suppl; 1996 May; (29):17-22. PubMed ID: 8733819 [No Abstract] [Full Text] [Related]
13. [Effect of treatment with psychotropic preparations on suppressor T-lymphocytes in juvenile continuously-progressing schizophrenia]. Mikheeva TV; Zemskova VV; Sekirina TP; Abramova LI Zh Nevropatol Psikhiatr Im S S Korsakova; 1985; 85(10):1550-2. PubMed ID: 2933909 [TBL] [Abstract][Full Text] [Related]
14. A group approach to psychopharmacology with schizophrenics. Skolnick MR Yale J Biol Med; 1985; 58(4):317-26. PubMed ID: 2864762 [TBL] [Abstract][Full Text] [Related]
15. Limitations of controlled augmentation trials in schizophrenia. Stern RG; Schmeidler J; Davidson M Biol Psychiatry; 1997 Jul; 42(2):138-43. PubMed ID: 9209731 [TBL] [Abstract][Full Text] [Related]
16. [The place of pyrogen therapy in the modern treatment of schizophrenia patients]. Malin DI Zh Nevropatol Psikhiatr Im S S Korsakova; 1992; 92(3):81-5. PubMed ID: 1332338 [TBL] [Abstract][Full Text] [Related]
17. Priority in the pharmacological management of chronic schizophrenia: the quality of life issues. Chiu E P N G Med J; 1982 Jun; 25(2):116-20. PubMed ID: 6961626 [TBL] [Abstract][Full Text] [Related]
18. [Pattern of prescriptions for psychopharmaceuticals to first-admission schizophrenic patients in the county of Arhus]. Lützhøft JH; Welinder L; Dybbro J; Skadhede S Ugeskr Laeger; 1996 Apr; 158(15):2118-22. PubMed ID: 8650785 [TBL] [Abstract][Full Text] [Related]
19. Psychotropic drug use in five city hospitals. Winstead DK; Blackwell B; Eilers MK; Anderson A Dis Nerv Syst; 1976 Sep; 37(9):504-9. PubMed ID: 971654 [No Abstract] [Full Text] [Related]
20. [Modification of long-term schizophrenia by somato-therapeutic measures]. Gross G; Huber G; Schüttler R Psychiatr Clin (Basel); 1980; 13(3-4):179-92. PubMed ID: 6113621 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]